ASH 2022 Conference Coverage
ASH 2022 Five-Year Survival Results From REMoDL-B: Outcomes in DLBCL Molecular Subgroups From the Addition of Bortezomib to R-CHOP Chemoimmunotherapy
By
ASH 2022 Conference Coverage
FEATURING
Andrew Davies
By
ASH 2022 Conference Coverage
FEATURING
Andrew Davies
Login to view comments.
Click here to Login
